SLC5A2 and anemia (phenotype): It is important to note that SGLT2 inhibitors provide significant benefits across various clinical end points, including reductions in heart failure events, hospitalizations, anemia, gout, hypertension, and mortality,5,22,23,24,25 and a lack of UACR response does not necessarily justify discontinuing dapagliflozin treatment.